REFERENCES

• LoosenPT.Hormones of hypothalamic-pituitary-thyroid axis: a psychoneuroendocrine perspective.Pharmacopsychiatry.1986194014183099318
   PubMed Web of Science ®Google Scholar
• JoffeRT.LevittAJ.The thyroid and depression. In Joffe RT, Levitt AJ, eds.The Thyroid Axis and Psychiatric Illness. Washington, DC: American Psychiatric Press;1993195254
   Google Scholar
• GriffithsEC.TRH: Endocrine and central effects.Psychoneuroendocrinol.198510225235
   PubMed Web of Science ®Google Scholar
• KastinAJ.EhrensingerH.SchalchDS.AndersonMS.Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone.Lancet.197227407424116150
   PubMed Web of Science ®Google Scholar
• Prange AJJr.WilsonIC.LaraBP.LiptonM.Effects of thyrotropin-releasing hormone and depression.Lancet.1972299910014116985
   PubMed Web of Science ®Google Scholar
• CoppenA.MontgomeryS.PeetM.BaileyJ.MarksV.WoodsP.Thyrotropin-releasing hormone in the treatment of depression.Lancet.197414334354131433
   PubMedGoogle Scholar
• EhrseningRH.KastinAJ.SchalchDS.FriesenHG.VargasJR.SchallyAV.Affective state and thyrotropin and prolactin responses after repeated imjections of thyrotropin-releasing hormone in depressed patients.Am J Psychiatry.19741317147184208055
   PubMed Web of Science ®Google Scholar
• HollisterLE.BergerP.OgleFL.ArnoldRC.JohnsonA.Protirelin (TRH) in depression.Arch Gen Psychiatry.1974314684704214026
   PubMed Web of Science ®Google Scholar
• MountjoyCQ.PriceJS.WellerM.HunterP.HallR.DewarJH.A doubleblind cross-over sequential trial of oral thyrotropin-releasing hormone in depression.Lancet.197429589604133645
   PubMedGoogle Scholar
• Van Den BurghW.Van PraagHM.BosERH.PiersDA.Van ZantenAK.DoorenbosH.Thyrotropin releaSing hormone (TRH) as a possible quick acting but short lasting antidepressant.Psychol Med.19755404412812133
   PubMed Web of Science ®Google Scholar
• FurlongFW.BrownGM.BeechingMF.Thyrotropin-releasing hormone: differential antidepressant and endocrinological effects.Am J Psychiatry.197613311871190823828
   PubMed Web of Science ®Google Scholar
• KieleyWF.AdrianAD.LeeJH.NicoloffJT.Therapeutic failure of oral thyrotropin-releasing hormone in depression.Psychosom Med.197638233241821075
   PubMed Web of Science ®Google Scholar
• Van Den BurghW.Van PraagHM.BosERH.PiersDA.van ZantenAK.DoorenbosH.TRH by slow, continuous infusion: an antidepressant?Psychol Med.19766393397825895
   PubMed Web of Science ®Google Scholar
• VogelHP.BenkertO.IlligR.Müller-OerlinghausenB.PoppenbergA.Psychoendocrinological and therapeutic effects of TRH in depression.Acta Psychiatr Scand.197756223232409101
   PubMed Web of Science ®Google Scholar
• KarlbergBE.KjelmanBF.KagedelB.Treatment of endogenous depression with oral thyrotropin-releasing hormone and amitriptyline.Acta Psychiatrica Scandinavica.197858389400102114
   PubMed Web of Science ®Google Scholar
• KhanA.MiroloMH.LaiH.et alECT and TRH: cholinergic involvement in a cognitive deficit state.Psychopharmacol Bull.1993293453528121962
   PubMedGoogle Scholar
• ChanBL.SingerW.The hypothalamic-pituitary-thyroid axis: Clinical and theoretical principles. In: Joffe RT, Levitt AJ, eds.The Thyroid Axis and Psychiatric Illness. Washington, DC: American Psychiatric Press;1993147165
   Google Scholar
• Prange AJJr.WilsonIC.KnoxA.McClaneTK.LiptonMA.Enhancement of imipramine by thyroid stimulating hormone: clinical and theoretical implications.Am J Psychiatry.19701271911995473147
   PubMed Web of Science ®Google Scholar
• FalchFF.CelianCI.RawsonRW.Treatment of psychiatric disorders with triiodothyronine.Am J Psychiatry.1958124341348
   Google Scholar
• Feldemeisser-ReissEE.The application of triiodothyronine in the treatment of mental disorders.J Nerv Ment Dis.195812754054613621222
   PubMed Web of Science ®Google Scholar
• Prange AJJr.WilsonIC.RaybonAM.LiptonM.Enhancement of the imipramine antidepressant activity by thyroid hormone.Am J Psychiatry.19691264574654185164
   PubMed Web of Science ®Google Scholar
• WilsonIC.Prange AJJr.McClaneTK.RabonAM.LiptonMA.Thyroid hormone enhancement of imipramine in non-retarded depression.N Engl J Med.1970282106310674908885
   PubMed Web of Science ®Google Scholar
• CoppenA.WhybrowPC.NogueraR.MaggsR.Prange AJJr.Comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine.Arch Gen Psychiatry.1972262342414551048
   PubMed Web of Science ®Google Scholar
• FeighnerJ.KingLJ.SchuckitMA.CroughanJ.BriscoeW.Hormonal potentiation of imipramine and ECT in primary depression.Am J Psychiatry.1972128123012384552204
   PubMed Web of Science ®Google Scholar
• WheatleyD.Potentiation of amitriptyline by thyroid hormone.Arch Gen Psychiatry.197226129
   Web of Science ®Google Scholar
• WilsonIC.Prange AJJr.McLeanTK.RabonAM.LiptonM.Thyroid hormone enhancement of imipramine in non-retarded depressions.N Engl J Med.19792821653
   Google Scholar
• EarleBV.Thyroid hormone and tricyclic antidepressants in resistant depression.Am J Psychiatry.1970126166716695443652
   PubMed Web of Science ®Google Scholar
• OguraC.OkumaT.UchidaY.ImiS.YogiH.Combined thyroid (triiodothyronine) tricyclic antidepressant treatment in depressive states.Folia Psychiatr Neurol JPN.1974281791864435675
   PubMedGoogle Scholar
• BankiCM.Triiodothyronine in the treatment of depression.Orv Hetil.1975116254325471187135
   PubMedGoogle Scholar
• BankiCM.Cerebrospinal fluid amine metabolytes after combined amitriptyline-tricyclic-thyronine treatment of depressed women.Eur J Clin Pharmacol.197711511515
   Web of Science ®Google Scholar
• TsutsuiS.YamazakiYNabaT.TsushimaN.Combined therapy of T3 and antidepressants in depression.J Int Med Res.197971138146113269
   PubMedGoogle Scholar
• GoodwinFK.PrangeAJ.PostRM.MuscettolaJ.LiptonMA.Potentiation of antidepressant effects by l-triiodothyronine and tricyclic non-responders.Am J Psychiatry.1982139154
   Web of Science ®Google Scholar
• SchwarczG.HalarisA.BaxterL.EscobarJ.ThompsonM.YoungM.Normal thyroid function in zipromine non-responders converted to responders by the addition of l-triiodothyronine.Am J Psychiatry.1984141161416166439059
   PubMed Web of Science ®Google Scholar
• GitlinMJ.VinerH.FairbanksL.HershmanM.FerifeldN.Failure of T3 to potentiate tricyclic antidepressant response.J Affect Disord.1987132672722960719
   PubMed Web of Science ®Google Scholar
• ThaseME.KupferDG.JarretDB.Treatment of imipramine resistant recurrent depression: I. An open clinical trial of adjunctive l-triiodothyronine.J Clin Psychiatry.1989503853882676995
   PubMed Web of Science ®Google Scholar
• JoffeRT.SingerW.A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.Psychiatry Res.1990322412512201988
   PubMed Web of Science ®Google Scholar
• JoffeRT.SingerW.LevittAJ.McDonaldC.A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.Arch Gen Psychiatry.1993503873918489327
   PubMed Web of Science ®Google Scholar
• BirkenhägerTK.VegtM.NolenWA.An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression.Pharmacopsychiatry.199712326
   Google Scholar
• AgidO.LererB.Algorithm-based treatment of major depression in an outpatient seelinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.Int J Neuropsychopharmacol.20036414912899735
   PubMed Web of Science ®Google Scholar
• AbrahamG.MilevR.Stuart LawsonJ.T3 augmentation of SSRI resistant depression.J Affect Disord.20069121121516483669
   PubMed Web of Science ®Google Scholar
• JoffeRT.SokolovST.LevittAJ.Lithium and triiodothyronine augmentation of antidepressants.Can J Psychiatry.20065179179317168254
   PubMed Web of Science ®Google Scholar
• NierenbergAA.FavaM.TrivediMH.et alA comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.Am J Psychiatry.20061631519153016946176
   PubMed Web of Science ®Google Scholar
• AronsonR.OffmanHJ.JoffeRT.NaylorCD.Triiodothyronine augmentation in the treatment of refractory depression.Arch Gen Psychiatry.1996538428488792761
   PubMed Web of Science ®Google Scholar
• Cooper-KazazR.LererB.Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors.Int J Neuropsychopharmacol.20081168569918047754
   PubMed Web of Science ®Google Scholar
• AppelhofBC.BrouwerJP.van DyckR.et alTriiodothyronine addition to paroxetine in the treatment of major depressive disorder.J Clin Endocrinol Metab.2004896271627615579788
   PubMed Web of Science ®Google Scholar
• Cooper-KazazAre.ApterJT.CohenR.et alCombined treatment with sertraline and liothyronine in major depression: a randomized, doubleblind, placebo-controlled trial.Arch Gen Psychiatry.20076467968817548749
   PubMed Web of Science ®Google Scholar
• PosternakM.NovakS.SternR.et alA pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response.Int J Neuropsychopharmacol.200811152517352847
   PubMed Web of Science ®Google Scholar
• BauerMS.HellwegR.GrafKJ.BaungartnerA.Treatment of refractory depression with high-dose of thyroxine.Neuropsychopharmacology.1998184444489571653
   PubMed Web of Science ®Google Scholar
• SpoovJ.LahdelmaI.Should thyroid augmentation proceed lithium augmentation? A pilot study.J Affect Disord.1998492352419629954
   PubMed Web of Science ®Google Scholar
• RudasAS.SchmitzM.PichlerP.BaungartnerA.Treatment of refractory chronic depression and dysthymia with high-dose thyroxine.Biol Psychiatry.1999452292359951571
   PubMed Web of Science ®Google Scholar
• LojkoD.RybakowskiJK.L-thyroxine augmentation of sertonergic antidepressants in female patients with refractory depression.J Affect Disrod.200710323256
   PubMed Web of Science ®Google Scholar
• AlmeidaOP.WaterreusA.SpryN.FlickerL.MartinsRN.One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.Psychoneuroendocrinology.2004291071108115219659
   PubMed Web of Science ®Google Scholar
• SchmidtPJ.BerlinKL.DanaceauMA.et alThe effects of pharmacologically induced hypogonadism on mood in healthy men.Arch Gen Psychiatry.200461997100415466673
   PubMed Web of Science ®Google Scholar
• AndersonRA.BancroftJ.WuFC.The effects of exogenous testosterone on sexuality and mood of normal men.J Clin Endocrinol Metab.199275150315071464655
   PubMed Web of Science ®Google Scholar
• BurrisAS.BanksSM.CarterCS.DavidsonJM.SherinsRJ.A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men.J Androl.1992132973041399830
   PubMedGoogle Scholar
• LuisiM.FranchiF.Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients.J Endocrinol Invest.19803305308
   PubMed Web of Science ®Google Scholar
• HarenMT.WittertGA.ChapmanIM.CoatesP.MorleyJE.Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status.Maturitas.20055012413315653010
   PubMed Web of Science ®Google Scholar
• SihR.MorleyJE.KaiserFE.Perry HM3rd.PatrickP.RossCL.Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.J Clin Endocrinol Metab.199782166116679177359
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorE.von MuhlenDG.Kritz-SilversteinD.Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study.J Clin Endocrinol Metab.19998457357710022418
   PubMed Web of Science ®Google Scholar
• DelhezM.HansenneM.LegrosJJ.Andropause and psychopathology: minor symptoms rather than pathological ones.Psychoneuroendocrinology.20032886387412892654
   PubMed Web of Science ®Google Scholar
• KanayamaG.HudsonJI.Pope HGJr.Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?Drug Alcohol Depend.20089811218599224
   PubMed Web of Science ®Google Scholar
• AltschuleM.TillotsonKJ.The use of testosterone in the treatment of depressions.N Engl J Med.19482391036103818103557
   PubMed Web of Science ®Google Scholar
• BarahalH.Testosterone in male involutional melancholia: preliminary report.Psychiatr Q.193812743749
   Google Scholar
• DanzigerL.SchroederHT.UngerA.Androgen therapy for involutional melancholia.Arch Neurol Psychiatry.194451457461
   Google Scholar
• DavidoffE.GoodstoneG.Use of testosterone propionate in treatment of involutional psychosis in the male.Arch Neurol Psychiatry.194248811817
   Google Scholar
• SeidmanSN.RabkinJG.Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression.J Affect Disord.1998481571619543205
   PubMed Web of Science ®Google Scholar
• SeidmanSN.SpatzE.RizzoC.RooseSP.Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial.J Clin Psychiatry.20016240641211465516
   PubMed Web of Science ®Google Scholar
• PerryPJ.YatesWR.WilliamsRD.et alTestosterone therapy in late-life major depression in males.J Clin Psychiatry.2002631096110112523867
   PubMed Web of Science ®Google Scholar
• Pope HGJr.CohaneGH.KanayamaG.SiegelAJ.HudsonJI.Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial.Am J Psychiatry.200316010511112505808
   PubMed Web of Science ®Google Scholar
• OrengoCA.FullertonL.KunikME.Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy.J Geriatr Psychiatry Neurol.200518202415681624
   PubMed Web of Science ®Google Scholar
• SeidmanSN.MiyazakiM.RooseSP.Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial.J Clin Psychopharmacol.20052558458816282843
   PubMed Web of Science ®Google Scholar
• SeidmanSN.OrrG.RavivG.et alEffects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial.J Clin Psychopharmacol.20092921622119440073
   PubMed Web of Science ®Google Scholar
• ShoresM.KivlahanDR.SadakTI.LiEJ.MatsumotoAM.A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression).J Clin Psychiatry.2009701009101619653976
   PubMed Web of Science ®Google Scholar
• PopeHGAmiazRBrennanB.et alParallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment.J Clin Psychopharmacol.20103012613420520285
   PubMed Web of Science ®Google Scholar
• MorgentalerA.Testosterone and prostate cancer: an historical perspective on a modern myth.Eur Urol.20065093593916875775
   PubMed Web of Science ®Google Scholar
• MorgentalerA.New concepts regarding the relationship of testosterone and prostate cancer.Future Oncol.2007312312617381410
   PubMedGoogle Scholar
• ChristianCA.MoenterSM.The neurobiology of preovulatory and estradiol-induced gonadotropin-releasing hormone surges.Endocr Rev.2010454457720237240
   PubMedGoogle Scholar
• MoenterSM.ChuZ.ChristianCA.Neurobiological mechanisms underlying oestradiol egative and positive feedback regulation of gonadotrophinreleasing hormone neurones.J Neuroendocrinol.2009432733319207821
   PubMedGoogle Scholar
• BiaginiG.PanuccioG.AvoliM.Neurosteroids and epilepsy.Curr Opin Neurol.2010317017620160650
   PubMedGoogle Scholar
• StuddJ.PanayN.Are oestrogens useful for the treatment of depression in women?Best Pract Res Clin Obstetr Gynaecol.2009236371
   PubMed Web of Science ®Google Scholar
• WittchenHU.BeckerE.LiebR.KrauseP.Prevalence incidence and stability of premenstrual dysphoric disorder in the community.Psychol Med.20023211913211883723
   PubMed Web of Science ®Google Scholar
• MacQueenG.ChokkaP.Special issues in the management of depression in women.Can J Psychiatry.200449(suppl 1)27S40S15147034
   PubMed Web of Science ®Google Scholar
• UsmanSB.IndusekharR.O'BrienS.Hormonal management of premenstrual syndromeBest Pract Res Clin Obstet Gynaecol.20082225126017761457
   PubMed Web of Science ®Google Scholar
• YonkersKA.O'BrienPM.ErikssonE.Premenstrual Syndrome.Lancet.20083711200121018395582
   PubMed Web of Science ®Google Scholar
• TommaselliGA.Di CarloC.BifulcoG.Di Spiezio SardoA.PellicanoM.NappiC.Serum leptin levels in patients with premenstrual syndrome treated with GnRH analogues alone and in association with tibolone.Clin Endocrinol (Oxf).20035971672214974912
   PubMed Web of Science ®Google Scholar
• MortolaJF.Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome.Clin Obstet Gynecol.1993367537638403622
   PubMed Web of Science ®Google Scholar
• RapkinA.A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder.Psychoneuroendocrinol.200328(suppl 3)3953
   PubMed Web of Science ®Google Scholar
• FreemanEW.KrollR.RapkinA.et alPMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.J Womens Health Gend Based Med.20011056156911559453
   PubMedGoogle Scholar
• GrahamCA.SherwinBB.A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive.J Psychosom Res.1992362572661564678
   PubMed Web of Science ®Google Scholar
• DickersonV.Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drosperinone.J Reprod Med.200247(suppl 11)98599312497673
   PubMed Web of Science ®Google Scholar
• HahnPM.Van VatDA.ReidRL.A randomised, placebo-controlled crossover trail of danazol for the treatment of premenstrual syndrome.Psychoneuroendocrinology.1995201932097899538
   PubMed Web of Science ®Google Scholar
• HalbriechU.RojanskyN.PalterS.Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndrome.Fertil Steril.199156106610691743323
   PubMed Web of Science ®Google Scholar
• O'BrienPMS.AukhalilIED.Randomised controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol.Am J Obstet Gynecol.199918018239914571
   PubMed Web of Science ®Google Scholar
• SichelDA.CohenLS.RobertsonLM.RuttenbergA.RosenbaumJF.Prophylactic estrogen in recurrent postpartum affective disorder.Biol Psychiatry.1995388148188750040
   PubMed Web of Science ®Google Scholar
• GregoireAJ.KumarR.EverittB.HendersonAF.StuddJW.Transdermal oestrogen for treatment of severe postnatal depression.Lancet.19963479309338598756
   PubMed Web of Science ®Google Scholar
• SchmidtRubinowP.DRSex hormones and mood in the perimenopause.Ann N Y Acad Sci.20091179708519906233
   PubMed Web of Science ®Google Scholar
• SchneiderL.SmallG.HamiltonS.BystritskyA.NemeroffC.MeyersB.Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group.Am J Geriatr Psychiatry.19975971069106373
   PubMed Web of Science ®Google Scholar
• SoaresC.PoitrasJ.ProutyJ.AlexanderA.ShifrenJ.CohenL.Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms.J Clin Psychiatry.20036447347912716252
   PubMed Web of Science ®Google Scholar
• SchneiderL.SmallG.ClaryC.Estrogen replacement therapy and antidepressant response to sertraline in older depressed women.Am J Geriatr Psychiatry.2001939339911739065
   PubMed Web of Science ®Google Scholar
• AmsterdamJ.Garcia-EspanaF.FawcettJ.et alFluoxetine efficacy in menopausal women with and without estrogen replacement.J Affect Disord.199955111710512601
   PubMed Web of Science ®Google Scholar
• SchmidtP.NiemanL.DanaceauM.et alEstrogen replacement in per imenopa use-related depression: a preliminary report.Am J Obstet Gynecol.200018341442010942479
   PubMed Web of Science ®Google Scholar
• WetterbergL.Melatonin in humans: physiological and clinical studies.J Neural Transm.197813(suppl)389410
   Google Scholar
• Wirz-JusticeA.Biological rhythm disturbances in mood disorders.Int Clin Psychopharmacol.200621(suppl 1)S11S1516436934
   PubMed Web of Science ®Google Scholar
• BrownG.SingerW.JoffeR.Lack of association between thyroid and pineal responses to antidepressant treatment.Depression.1996473769160644
   PubMedGoogle Scholar
• SackRL.BrandesBS.KendallBS.LewyAJ.Entrainment of freerunning circadian rhythms by melatonin in blind people.N Engl J Med.20003431070107711027741
   PubMed Web of Science ®Google Scholar
• LewyAJ.BauerVK.CutlerNL.SackRL.Melatonin treatment of winter depression: a pilot study.Psychiatry Res.199777576110710176
   PubMed Web of Science ®Google Scholar
• RosenthalNE.SackDA.JamesSP.ParryBL.MendelsonWB.TamarkinL.Seasonal affective disorder and phototherapy.Ann NY Acad Sci.19854532602693865586
   PubMed Web of Science ®Google Scholar
• CarmanJS.PostRM.BuswellR.GoodwinFK.Negative effects of melatonin on depression.Am J Psychiatry.197613311811186788529
   PubMed Web of Science ®Google Scholar
• De VriesMW.PeetersFPML.Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression.J Nerv Ment Dis.19971852012029091602
   PubMed Web of Science ®Google Scholar
• FainsteinI.BonettoAJ.BruscoLI.CardinaliDP.Effects of melatonin in elderly patients with sleep disturbance: a pilot study.Curr Ther Res.1997589901000
   Web of Science ®Google Scholar
• DolbergOT.HirschmannS.GrunhausL.Melatonin for the treatment of sleep disturbances in major depression.Am J Psychiatry.1998155111911219699707
   PubMed Web of Science ®Google Scholar
• DaltonEJ.RotondiD.LevitanRD.KennedySH.BrownGM.Use of slow release melatonin in treatment resistant depression.J Psychiatry Neurosci.200025485210721684
   PubMed Web of Science ®Google Scholar
• SerfatyMA.OsborneD.BuszewiczMJ.RavenPW.The effect of exogeneous melatonin in major depression.Chronobiol Int.20032011911192
   Google Scholar
• BellipanniGFDIM.BlasiF.Di MarzoA.A Effects of melatonin in perimenopausal and menopausal women: our personal experience.Ann N Y Acad Sci.2005105739340216399909
   PubMed Web of Science ®Google Scholar
• KasperS.HajakG.WulffK.Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.J Clin Psychiatry.20107110912020193645
   PubMed Web of Science ®Google Scholar
• LooH.HaleA.D'haenenH.Determination of the dose of agomelatine, a melatonergic agonist and selective 5HT2c antagonistic, in the treatment of major depressive disorder: a placebo-controlled dose range study.Int Clin Psychopharmacol.20021723924712177586
   PubMed Web of Science ®Google Scholar
• KlingMA.ColemanVH.SchulkinJ.Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?Depress Anxiety.20092664164919133699
   PubMed Web of Science ®Google Scholar
• LemoineP.GuilleminaultC.AlvarezE.Improvement of subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.J Clin Psychiatry.2007681723173218052566
   PubMed Web of Science ®Google Scholar
• HaleA.CorralRM.MencacciC.RuizJS.SeveroCA.GentilV.Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized double-blind study.Int Clin Psychopharmacol.20102530531420856123
   PubMed Web of Science ®Google Scholar
• MurphyBE.Treatment of major depression with steroid suppressive drugs.J Steroid Biochem Mol Biol.1991392392441888684
   PubMed Web of Science ®Google Scholar
• GhadirianAM.EnglesmannF.DharV.et alThe psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.Biol Psychiatry.1995373693757772645
   PubMed Web of Science ®Google Scholar
• WolkowitzOM.ReusVI.ChanT.ManfrediF.RaumW.JohnsonR.CanickJ.Antiglucocorticoid treatment of depression: double-blind ketoconazole.Biol Psychiatry.1999451070107410386195
   PubMed Web of Science ®Google Scholar
• ThakoreJH.DinanT.Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression.Biol Psychiatry.1995373643687772644
   PubMed Web of Science ®Google Scholar
• O'DwyerAM.LightmanSL.MarksMN.CheckleySA.Treatment of major depression with metyrapone and hydrocortisone.J Affect Disord.1995331231287759660
   PubMed Web of Science ®Google Scholar
• JahnH.SchickM.KieferF.KellnerM.YassouridisA.WiedemannK.Metyrapone as additive treatment in major depression: a double-blind and placebocontrolled trial.Arch Gen Psychiatry.2004611235124415583115
   PubMed Web of Science ®Google Scholar
• FloresBH.KennaH.KellerJ.SolvasonHB.SchatzbergAF.Clinical and biological effects of mifepristone treatment for psychotic depression.Neuropsychopharmacology.20063162863616160710
   PubMed Web of Science ®Google Scholar
• DeBattistaC.BelanoffJ.The use of mifepristone in the treatment of neuropsychiatric disorders.Trends Endocrinol Metab.20061711712116530421
   PubMed Web of Science ®Google Scholar
• HolsboerF.IsingM.Central CRH system in depression and anxietyevidence from clinical studies with CRH1 receptor antagonists.Eur J Pharmacol.200858335035718272149
   PubMed Web of Science ®Google Scholar
• HolsboerF.The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.J Psychiatr Res.19993318121410367986
   PubMed Web of Science ®Google Scholar
• RushAJ.TrivediMH.WisniewskiSR.et alSTAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.N Engl J Med.20063541231124216554525
   PubMed Web of Science ®Google Scholar